Composition, structure and packing

Concentrate for solution for topical application of 1 ml poligeksanid 200 mg of pH 5.0-7.0. Excipients: Water d / and macrogol 400 (polyethylene glycol) 10 mg.

Clinico-pharmacological group: Antiseptic for external use

Pharmacological action

Antiseptic drugs. Poligeksanid has a broad spectrum of antimicrobial action. It is active against Gram positive and Gram-negative bacteria (including Pseudomonas aeruginosa), fungi.

Polyethylene glycol (PEG) reduces the surface tension, which contributes to the action poligeksanida.

In the presence of protein (0.2% albumin), drug effect is weakened only slightly, and in conducting quantitative tests revealed good fungicidal and bactericidal effect.

The product does not contain substances possessing irritating action: halogen and mercury-containing antiseptics, iodine, heavy metals, polyvinylpyrrolidone and aldehydes.

Poligeksanid chemically stable, not volatile, odorless, soluble in water, ethanol, glycerol, propylene glycol and other solvents.

Poligeksanid has low toxicity, and the content of polyethylene glycol in Lavasepte concentrate little to enhance the toxicity poligeksanida.


For exterior use suction system was not observed (the concentration of active substance in the blood and urine was below 10 mg / ml - possible level of definition). Also, it was not detected in cases of permanent irrigation or irrigation of extensive surgical wounds during operations, which lasted 2 hours or more without the use of tourniquet.

Systemic absorption was not determined, and the use of dressings with the drug for wound dressing for several weeks (1 case the maximum period was 58 weeks).

antiseptic treatment in the surgical treatment of infected wounds and superficial injuries of soft tissues;
lavage of the cavities through the drainage tube with an active drainage;
irrigation of the operative field during surgical intervention for reconstructive operations immediately prior to transplantation of bone and soft tissues;
irrigation of the operative field during operations with the existing threat of infection;-treatment of infected wounds during the operation hip replacement (by Schneider);
antiseptic protection of open wounds;
treatment of burn surfaces;
antiseptic treatment during maxillofacial operations;
Processing of surgical instruments, dressings and health products.

Dosage regimen

Lavasept concentrate used only externally. Before applying Lavasept concentrate must be diluted to a concentration of 0.1% or 0.2%.

For irrigation and drainage of wounds should use 0.1% solution Lavasepta concentrate.

In the case of infection with gram-negative flora of wounds using 0.2% solution of the drug.

Terms of solution preparation

For preparation of 0.1% or 0.2% solution Lavasepta to 1000 ml of Ringer's solution should be added to 1 ml or 2 ml of concentrate Lavasepta. When mixed with other solutions should be avoided turbidity and precipitation. Precipitated at low temperatures poligeksanid can be dissolved in the solution is heated to 60 ° C.

Side effect

Allergic reactions: skin rash, urticaria.

operations on non-infected joints;
operations on the brain and spinal cord (neurosurgical operations);
operations in the middle and inner ear;
operations on the eyes (ophthalmic surgery);
intraperitoneal lavage;
Hypersensitivity to the drug's components.

Pregnancy and lactation

There is currently no sufficient data on the use Lavasepta concentrate during pregnancy and lactation. Do not use the drug in the I trimester of pregnancy. In the later stages of pregnancy and lactation may be used only if the intended benefits to the mother exceeds potential risk to the fetus or child.


If you have any allergic reactions use Lavasepta concentrate should immediately cease and to appoint an anti-allergic therapy (antihistamines).

In applying Lavasepta concentrate to avoid delay in its tissues.

In experimental studies on animals have shown that Lavasept concentrate inhibits the growth of cartilage tissue of embryos. Prolonged use Lavasept can cause damage to the intact cartilage. Therefore, you should not use Lavasept concentrate for washing uninfected joints. If you accidentally hit the drug on the intact cartilage during joint operations in the uninfected entire joint should be washed with Ringer's solution or saline solution.

Using Lavasepta concentrate on the inflamed and infected joints, with significant lesions in cases where the planned arthrodesis or total joint replacement, Lavasept concentrate can create the optimal level of disinfection, which provides a favorable outcome of the operation.

Use in Pediatrics

In pediatric use 0.1% solution Lavasepta concentrate. In the absence of experience with Lavasepta concentrate in children aged under 3 years of drug use in patients in this age group is possible only after careful evaluation of risk-benefit ratio.


Cases of overdose have not been described.

Drug Interactions

Currently, cases of drug interactions are not known.

Terms and Conditions of storage

The drug should be stored at a temperature of 8 ° to 25 ° C. Do not freeze.

Shelf life - 3 years.

The prepared solution must be used within 48 hours